Indazole derivatives for treating TRPM3-mediated disorders
JP2025518048A5Pending Publication Date: 2026-05-29KATHOLIEKE UNIV LEUVEN +1
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- KATHOLIEKE UNIV LEUVEN
- Filing Date
- 2023-05-25
- Publication Date
- 2026-05-29
AI Technical Summary
Technical Problem
Current therapies for TRPM3-mediated disorders, such as pain and epilepsy, often have limitations including side effects, potential for dependence, and suboptimal pharmacokinetic or pharmacodynamic properties.
Method used
Development of novel indazole derivatives that act as antagonists of TRPM3, offering potential as modulators for the prevention or treatment of TRPM3-mediated disorders.
Benefits of technology
The indazole derivatives demonstrate efficacy in addressing TRPM3-mediated disorders with a focus on improving therapeutic outcomes by minimizing side effects and enhancing pharmacological properties.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2023230540000001 
Figure 2023230540000002 
Figure 2023230540000003
Abstract
The present invention relates to a compound useful for the prevention or treatment of a TRPM3-mediated disorder, more specifically a disorder selected from pain and inflammatory hypersensitivity. The present invention also relates to a method for the prevention or treatment of said TRPM3-mediated disorder.
Need to check novelty before this filing date? Find Prior Art